Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial-II, most patients with SLN+ melanoma no longer un...

Full description

Bibliographic Details
Main Authors: Yun Song, John F Thompson, Frances A Collichio, Tasha Hughes, John Vetto, Dale Han, Jonathan Zager, Zeynep Eroglu, Jennifer Downs, David E Gyorki, Nikhil I Khushalani, Alexander van Akkooi, Georgia Beasley, Lisa Kottschade, Hidde M Kroon, Ann Lee, Norma E Farrow, Giorgos Karakousis, Michael Lowe, Avinash Sharma, Kristy K Broman, Amanda Nijhuis, Tina J Hieken, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Lesly Dossett, Russell S Berman, Emma Stahlie, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, David W Ollila, Roger Olofsson Bagge, Jan Mattsson, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/8/e004417.full

Similar Items

Similar Items